{"version":3,"file":"uavLNJeQy.CW99ABmF.mjs","names":[],"sources":["https:/framerusercontent.com/modules/jMytFVdcoBkGYKREmVs2/KGflnKQXQ4OA2sS5jGCk/uavLNJeQy.js"],"sourcesContent":["// Generated by Framer (293632e)\nexport default function metadata(params,activeLocale){return{breakpoints:[{hash:\"1uyseb4\",mediaQuery:\"(min-width: 1138px)\"},{hash:\"1ujf58c\",mediaQuery:\"(min-width: 810px) and (max-width: 1137.98px)\"},{hash:\"e17t55\",mediaQuery:\"(max-width: 809.98px)\"}],description:\"A robust, comprehensive global IP portfolio centered on our Galectin-3 targeted apheresis platform.\",elements:{gHeffzhgr:\"navtrigger\"},framerSearch:{index:true},robots:\"max-image-preview:large\",serializationId:\"framer-RYPJY\",title:\"Intellectual Property - Eliaz Therapeutics\",viewport:\"width=device-width\"};}export const metadataVersion=1;\nexport const __FramerMetadata__ = {\"exports\":{\"metadataVersion\":{\"type\":\"variable\",\"annotations\":{\"framerContractVersion\":\"1\"}},\"default\":{\"type\":\"function\",\"annotations\":{\"framerContractVersion\":\"1\"}},\"__FramerMetadata__\":{\"type\":\"variable\"}}}"],"mappings":"oDACA,SAAwB,EAAS,EAAO,EAAa,CAAC,MAAM,CAAC,YAAY,CAAC,CAAC,KAAK,UAAU,WAAW,sBAAsB,CAAC,CAAC,KAAK,UAAU,WAAW,gDAAgD,CAAC,CAAC,KAAK,SAAS,WAAW,wBAAwB,CAAC,CAAC,YAAY,sGAAsG,SAAS,CAAC,UAAU,aAAa,CAAC,aAAa,CAAC,MAAM,GAAK,CAAC,OAAO,0BAA0B,gBAAgB,eAAe,MAAM,6CAA6C,SAAS,qBAAqB,mBAAe,EAAgB,EAC7kB,EAAqB,CAAC,QAAU,CAAC,gBAAkB,CAAC,KAAO,WAAW,YAAc,CAAC,sBAAwB,IAAI,CAAC,CAAC,QAAU,CAAC,KAAO,WAAW,YAAc,CAAC,sBAAwB,IAAI,CAAC,CAAC,mBAAqB,CAAC,KAAO,WAAW,CAAC,CAAA"}